

Incannex Pharmaceuticals™ by Impression Secures Long Term Medicinal Cannabis Oil Supply Agreement

Highlights:

- Impression Health ('Impression', 'IHL' or the 'Company') has officially launched its wholly owned novel cannabinoid drug discovery brand **Incannex Pharmaceuticals™** ('Incannex')
- Incannex has engaged **Linnea SA ('Linnea')** an EU-based, global leader in custom cannabinoid drug design and formulation to be their supply partner for base cannabinoid materials for two of its four novel cannabinoid formulations under design - TMJ Disorder and TBI/Concussion
- Incannex by Impression's four areas of cannabinoid research and imminent clinical trials include:
 - Obstructive Sleep Apnoea
 - Traumatic Brain Injury (TBI)/Concussion
 - Temporomandibular Joint (TMJ) Disorder
 - Periodontitis (Gum Disease) and Gingivitis.

In parallel with IHL's clinical trials being undertaken to create four proprietary, IP-defendable products, IHL under the Incannex brand, has also launched a line of EU GMP-approved pharmaceutical grade CBD Oil products to treat conditions previously approved for treatment with cannabinoids under Special Access Scheme ('Incannex Oils'). These Incannex Oils can be sold under Australia's largest distribution network – Cannvalate - on a non-exclusive basis.

- Incannex will purchase up to 2000, 50ml bottles of Incannex Oils over the remainder of the 2019 calendar year; increasing over an initial 5-year term of the contract until 2024
- The Incannex Oils have been designed to match with the formulations most in demand on the Cannvalate network, which receives 100+ new patient enquiries per day
- The TGA Special Access Scheme (SAS-B) Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019
- Incannex has adopted a commercial strategy to acquire 1000 patients by the end of 2019 which would make it one of the largest Licensed Cannabis Companies in Australia.

Impression's Relationship with Cannvalate Pty Ltd

The CBD supply agreement augments with IHL's existing product supply and distribution agreement and equity relationship with Cannvalate Pty Ltd ('Cannvalate'), the largest distributor of medicinal cannabis products in Australia, representing over 40% of the entire market.


On the 21st of March 2019, Impression executed a comprehensive agreement with Cannvalate; including a wholesale purchase and distribution agreement for the sale of cannabis medicines into its growing network of medical professionals. As a part of that relationship, Impression has granted Cannvalate various series of options, subject to shareholder approval at the upcoming EGM, with exercise prices ranging up to \$0.14 per share; aligning the interests of the two companies.

On the 25th of July 2019, Impression appointed Dr Sud Agarwal, the CEO and Chairman of Cannvalate, to the board of Impression. Dr Agarwal is also the Chief Medical Officer of Impression and an internationally recognised key opinion leader in the clinical use of cannabinoid medicines; overseeing IHL’s four clinical trials.

Dr Sud Agarwal said, “Impression Health and Incannex have realised that the two largest determinants of future growth for cannabis companies are **patient acquisition** and **creation of patent-secured, novel cannabinoid products** which have been scientifically validated by clinical trials. Incannex are on target to race ahead on both fronts by the end of 2019.”

TGA Special Access Scheme Category B Sales and Impression Branded CBD Oil

TGA Special Access Scheme Category B Sales for medicinal cannabis products have increased 229% from 670 approvals in January of 2019 to 2206 approvals in July of 2019.



Note: Major growth in TGA Special Access Scheme Category B Approvals.

Impression Healthcare CEO and Managing Director, Mr Joel Latham said; “We’ve just seen a record-breaking month for TGA approvals of cannabinoid medicines in Australia and expect to see further growth in patient numbers resulting from increased public awareness; particularly positive media coverage on patient outcomes. We’re delighted to have forged this agreement with Linnea, who we consider to be one of the highest-quality producers of GMP-approved medicinal cannabis products in the world.

Following the completion of the supply agreement, Impression expects to play a significant role in the fast-growing market for high-quality medicinal cannabis oils to provide relief to patients in need.

Further to this, the Linnea will assist us with formulating and manufacturing IP-defendable products for 2 of our clinical trials. Creating products with defendable IP provides us a significant opportunity to develop long lasting

products targeted at specific indications. It also provides us the opportunity to create long-term value for shareholders upon clinical trial success.”

About Linnea SA

Located in the Swiss Canton of Ticino, Linnea is a high-quality manufacturer of botanical Extracts and Pharmaceutical Ingredients of natural origin for use in the pharmaceutical, nutraceutical and cosmetic industries.

Linnea manufactures Herbal Extracts, Purified Ingredients and Semi-synthetic APIs of Natural Origin and comply with international standards at a Swiss-based GMP facility.

The Linnea extraction plant was built in 1980 by an Italian entrepreneur. The existing production facilities were converted from a chemical to a phytochemical plant, specializing in botanical extractions and semi-synthesis processes. The company was named Linnea with reference to Carl Nilsson Linnaeus.

In 1990 Linnea was acquired by a Joint Venture of Schwabe (Schwabe.de) and Ipsen (Ipsen.fr). The new shareholder invested new capital to develop Linnea’s production capacity and to improve quality and safety standards.

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is an innovative healthcare company that sells customised oral devices both direct-to-the-consumer and via the Company’s growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth-protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has broadened its commitment to disruption in the healthcare sector by progressing multiple opportunities in the field of medicinal cannabis. IHL has its licenses in place to import, export and distribute cannabis products. In March of 2019, Impression executed a binding collaboration with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. Cannvalate is Australia’s largest distributor of medicinal cannabis products.

IHL also has a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated; a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand; and also intends to distribute medicinal cannabis oils through the Cannvalate network of cannabis medicine prescribers throughout Australia.

Investors: investors@impression.healthcare

Website: www.impression.healthcare